We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

61 hedge funds and large institutions have $1.12B invested in Prelude Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

27.54% more ownership

Funds ownership: 73.38% → 100.92% (+28%)

14% more capital invested

Capital invested by funds: $986M → $1.12B (+$138M)

7% more funds holding

Funds holding: 57 → 61 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
61
Holders Change
+4
Holders Change %
+7.02%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
9
Increased
25
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.3M
3
Norges Bank
Norges Bank
Norway
+$6.39M
4
UBS AM
UBS AM
Illinois
+$6.33M
5
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$3.14M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$6.53M
2
Citigroup
Citigroup
New York
-$1.66M
3
Deutsche Bank
Deutsche Bank
Germany
-$991K
4
RSCM
Rock Springs Capital Management
Maryland
-$648K
5
Voloridge Investment Management
Voloridge Investment Management
Florida
-$439K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
51
Legal & General Group
United Kingdom
$92K +$59.6K +1,841 +165%
SO
52
STRS Ohio
Ohio
$68K – – –
PHK
53
Point72 Hong Kong
Hong Kong
$50K +$51.9K +1,602 New
AIP
54
Ameritas Investment Partners
Nebraska
$24K – – –
SOW
55
State of Wyoming
Wyoming
$18K -$8.94K -276 -33%
Osaic Holdings
56
Osaic Holdings
Arizona
$11K – – –
JCM
57
Jacobi Capital Management
Pennsylvania
$8K – – –
QT
58
Quantbot Technologies
New York
$6K +$6.47K +200 New
US Bancorp
59
US Bancorp
Minnesota
$5K +$5.12K +158 New
Wells Fargo
60
Wells Fargo
California
$2K – – –
PA
61
Parallel Advisors
California
$1K +$194 +6 +19%
Voloridge Investment Management
62
Voloridge Investment Management
Florida
– -$439K -15,319 Closed
JF
63
Jump Financial
Illinois
– -$392K -13,700 Closed
Two Sigma Investments
64
Two Sigma Investments
New York
– -$290K -10,116 Closed
AIP
65
ARS Investment Partners
New York
– -$212K -7,400 Closed
DFCM
66
Dark Forest Capital Management
Puerto Rico
– -$4K -155 Closed
1 2
3

PRLD Hedge Fund Activity: Q3 2021 in Review

61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q3 2021, worth a combined $1.12B — up 14% from $986M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PRLD positions and 5 closed out — a net gain of 4 holders — while 25 added to existing stakes and 13 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $20.2M. The largest seller was State Street, cutting an estimated $6.53M.

  • 61 institutional investors held Prelude Therapeutics (PRLD) as of Q3 2021, up from 57 in Q2 2021.
  • Funds reported $1.12B of Prelude Therapeutics stock for Q3 2021, up 14% quarter-over-quarter.
  • 9 funds opened new Prelude Therapeutics positions in Q3 2021 and 5 closed out, a net change of +4 holders.
  • The largest Prelude Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $20.2M added.
  • The largest Prelude Therapeutics seller in Q3 2021 was State Street, an estimated $6.53M sold.

Based on aggregated 13F filings for Q3 2021.